Outcomes and Prognosis of COVID-19-Induced Adult Respiratory Distress Syndrome Patients Treated with Prolonged Veno-Venous Extracorporeal Membrane Oxygenation: A Retrospective Multicenter Study.

Outcomes and Prognosis of COVID-19-Induced Adult Respiratory Distress Syndrome Patients Treated with Prolonged Veno-Venous Extracorporeal Membrane Oxygenation: A Retrospective Multicenter Study.

Publication date: Nov 28, 2024

Background: Predicting whether extracorporeal membrane oxygenation (ECMO) treatment duration affects prognosis is important both medically and economically. Methods: We conducted a retrospective, multicenter study to better understand the outcomes of patients treated with veno-venous (VV) ECMO over a prolonged duration, analyzing data from the Israel ECMO registry. The study included all adult patients treated with VV-ECMO due to COVID-19-induced respiratory failure. The primary outcomes were survival rates up to 180 days from cannulation. Results: One hundred and eighty-eight patients were included in the study. The median age was 50 years (IQR 42, 50), and 69% were male. Patients were mechanically ventilated for a median of 2. 5 days before cannulation (IQR 0. 5, 5). The mean ECMO support duration was 29. 9 days, with a maximal duration of 189. 9 days. The survival rate for 180 days was 56%. We found no change in survival for patients on ECMO for 14, 28, or 56 days. Every day of mechanical ventilation before cannulation correlated with an 11% greater risk for prolonged ECMO treatment (p = 0. 01). Conclusions: COVID-19-induced ARDS patients treated with VV-ECMO for prolonged duration had the same prognosis as those treated for short periods of time. The longer the duration of mechanical ventilation before ECMO cannulation, the higher the risk for prolonged ECMO treatment.

Open Access PDF

Concepts Keywords
Covid ARDS
Israel COVID-19
Medically prolonged ECMO
Retrospective

Semantics

Type Source Name
disease MESH COVID-19
disease MESH Adult Respiratory Distress Syndrome
drug DRUGBANK Tropicamide
disease MESH respiratory failure
drug DRUGBANK Trestolone
drug DRUGBANK Coenzyme M
drug DRUGBANK Nitric Oxide
disease IDO blood
disease MESH complications
drug DRUGBANK Heparin
disease MESH thrombocytopenia
disease MESH thrombosis
disease MESH bleeding
disease MESH infections
disease MESH pneumonia
disease MESH bacteremia
disease MESH death

Original Article

(Visited 1 times, 1 visits today)